Welcome to our dedicated page for Prelude Therapeutics news (Ticker: PRLD), a resource for investors and traders seeking the latest updates and insights on Prelude Therapeutics stock.
Prelude Therapeutics Inc (PRLD) is a clinical-stage biopharmaceutical company advancing precision oncology through targeted small molecule therapies. This dedicated news hub provides stakeholders with verified updates on clinical developments, research breakthroughs, and corporate milestones.
Find comprehensive coverage of PRLD's innovative pipeline including SMARCA2 protein degraders and selective CDK9 inhibitors, alongside strategic collaborations shaping cancer treatment paradigms. Our curated news selection prioritizes factual reporting on trial progress, regulatory communications, and partnership announcements without speculative content.
Key updates include phase 1 clinical data, scientific conference presentations, and manufacturing developments. Bookmark this page for efficient tracking of PRLD's progress in addressing high-unmet medical needs through molecularly targeted approaches.
Prelude Therapeutics (Nasdaq: PRLD) reported significant advancements in its clinical pipeline during 2022, highlighting four differentiated compounds in Phase 1 trials. The company aims to present initial data from its PRT2527 and PRT1419 programs at the upcoming AACR Annual Meeting. As of December 31, 2022, Prelude's cash reserves stood at $201.7 million, sufficient to fund operations through Q4 2024. Research and development expenses increased to $92.9 million, while general and administrative costs rose to $30.7 million. The company posted a net loss of $115.4 million for the fiscal year, slightly higher than the previous year.
Prelude Therapeutics (Nasdaq: PRLD) announced a clinical trial collaboration with BeiGene to evaluate its CDK9 inhibitor, PRT2527, alongside BeiGene's BTK inhibitor, zanubrutinib, for treating hematologic malignancies. This collaboration is based on recent evidence showing enhanced efficacy of CDK9 and BTK inhibition in B cell malignancies.
Prelude retains all operational and commercial rights for PRT2527 while BeiGene provides zanubrutinib. PRT2527 is currently undergoing a Phase 1 dose-escalation study for advanced solid tumors and hematologic malignancies, demonstrating potential as a selective and potent treatment option.
Prelude Therapeutics, a clinical-stage precision oncology company, announced its participation in the Barclays Global Healthcare Conference in Miami from March 14 to 16, 2023. On March 16 at 9:30 a.m. ET, CEO Kris Vaddi and CMO Jane Huang will engage in a fireside chat. One-on-one meetings are scheduled for March 15 and 16.
Prelude focuses on developing innovative drug candidates targeting critical cancer pathways, with a pipeline featuring four candidates: PRT1419, PRT2527, PRT3645, and PRT3789.
Prelude Therapeutics announced its participation in three healthcare investment conferences in February 2023. On February 14, CEO Kris Vaddi and CMO Jane Huang will engage in a fireside chat at the SVB Securities Global Biopharma Conference, followed by one-on-one investor meetings. On February 21, executives will participate in the 2023 Wells Fargo Targeted Protein Degradation Summit, with talks focusing on key protein degradation targets in oncology. Prelude is a clinical-stage oncology company with a pipeline of innovative drug candidates, including PRT1419 and PRT3879, aimed at addressing critical cancer pathways.
Prelude Therapeutics announced FDA clearance for two new INDs: PRT3789, a selective SMARCA2 degrader, and PRT3645, a next-gen CDK4/6 inhibitor. The company plans to discontinue the PRMT5 program to focus on high-potential candidates. With cash and equivalents of $224 million, Prelude expects this to fund operations into Q4 2024. For Q3 2022, R&D expenses slightly increased to $22.9 million while G&A expenses decreased to $7.5 million. The net loss was $30 million, or $0.63 per share, compared to a loss of $30.7 million, or $0.66 per share, in the previous year.
Prelude Therapeutics (Nasdaq: PRLD) announced FDA clearance to proceed with a Phase 1 study for PRT3789, a selective SMARCA2 protein degrader targeting advanced solid tumors. The trial will start dosing in Q1 2023 and focus on patients with SMARCA4 mutations, particularly non-small cell lung cancer. Key endpoints include safety, tolerability, and pharmacokinetics. The clearance is seen as a significant advancement for Prelude as it targets an urgent need for therapies for aggressive cancers without other actionable genetic alterations.
Prelude Therapeutics Incorporated (Nasdaq: PRLD) is set to participate in two significant healthcare investment conferences in New York City next week. On September 12, CEO Kris Vaddi will engage in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference, with one-on-one meetings on September 13. The following day, Vaddi and CMO Dr. Jane Huang will participate in a chat at the Morgan Stanley Global Healthcare Conference, along with additional investor meetings. Prelude is focused on developing innovative oncology drug candidates targeting critical cancer pathways.
Prelude Therapeutics announced the acceptance of its Investigational New Drug (IND) application for PRT3645, a novel brain-penetrant CDK4/6 inhibitor, by the FDA. The Phase 1 trial is set to commence in Q4 2022, targeting various cancers. As of June 30, 2022, the company reported strong cash reserves of $246.3 million, sufficient to fund operations into the second half of 2024. R&D expenses decreased to $21.3 million, while G&A expenses rose to $8.2 million, resulting in a net loss of $27.4 million for Q2 2022. Upcoming milestones include updates on the PRMT5 and MCL1 inhibitor programs.
Prelude Therapeutics reported a strong cash position of $266.2 million as of March 31, 2022, expected to fund operations into 2H2024. The company provided updates on its clinical pipeline, including the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527, all on track for significant milestones in 2H2022. Research and Development expenses rose to $22.8 million, while General and Administrative expenses increased to $7.5 million. The net loss for the quarter was $29.5 million, or $0.63 per share, reflecting higher operational costs.
Prelude Therapeutics (Nasdaq: PRLD) reported significant progress in 2021, expanding its pipeline to six internally discovered small molecule compounds targeting cancer pathways. The company aims to demonstrate proof-of-concept data for these compounds in 2022. With cash reserves of $291.2 million, Prelude anticipates funding operations into the second half of 2024. However, R&D expenses rose to $86.8 million, and net losses increased to $111.7 million, or $2.43 per share. Strategic prioritization includes focusing on lead candidate PRT811 in the PRMT5 program.